What Doppel Farmeceutici does

Doppel Farmaceutici S.r.l. is an Italian contract development and manufacturing organization (CDMO) headquartered in Cortemaggiore, Piacenza, serving global pharmaceutical clients with vertically integrated services spanning formulation development, regulatory support, production, and packaging. Founded in 1994 and backed by Trilantic Europe, the company operates two manufacturing sites — a 44,000 sqm primary facility in Cortemaggiore and a 25,000 sqm facility in Milan/Rozzano (acquired from Pfizer in 2001) — totaling 69,000+ sqm of manufacturing footprint, 19-20 production lines, and annual capacity for 100 million packages. Production capabilities span solid dosage forms (tablets, capsules with HPAPI handling), semi-solids (creams, gels with CIP/SIP), liquids and sprays (syrups, nasal sprays), sterile injectables (aseptic filling to EMA/FDA standards), and Class I-III medical devices, with associated brand Alfa Omega manufacturing Class III injectable devices.

The company employs 580+ staff, including 29 dedicated R&D scientists and 124 quality assurance and control professionals, supported by ISO-certified labs at three sites. Doppel's business model is project-based B2B contract manufacturing: pricing is negotiated per project on formulation complexity, volume, and regulatory scope rather than published. Customer segments include global pharmaceutical companies seeking CDMO partners for complex formulations, regulatory navigation, and flexible capacity, plus startups, academic spin-offs, and research centers served through a dedicated Startup & Academia program offering co-development, prototyping, and stability testing. Compliance with EMA, FDA, AIFA, GMP/GLP, and five ISO standards (9001, 13485, 14001, 22001, 45001) anchors the value proposition, supplemented by an April 2025 Ecovadis Sustainability certification.

In July 2024, Trilantic Europe and Alto Partners announced the merger of Doppel with Mipharm to form Domixtar Pharmaceuticals (DMX Pharma), positioning the combined entity as the largest independent Italian CDMO with approximately €180 million in 2023 combined turnover; completion was expected by September 2024. The company previously acquired a 90% stake in Dietopack in 2020, expanding its CDMO footprint. Distribution is exclusively direct B2B sales to enterprise pharmaceutical buyers globally.

Name

Doppel Farmeceutici

Legal name

Doppel Farmaceutici S.r.l.

Website

https://doppel.it

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

251–500 employees

Short description

Doppel Farmaceutici is an Italian contract development and manufacturing organization (CDMO) serving global pharmaceutical clients with integrated formulation, production, and packaging services across solid, semi-solid, liquid, injectable, and medical device dosage forms from two Italian manufacturing sites.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

akta.pro secondary industries

Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

Keywords

• Contract pharmaceutical manufacturing
• Pharmaceutical contract development
• Pharmaceutical packaging services
• Sterile injectable manufacturing
• Pharmaceutical formulation services

Headquarters

HQ city

Cortemaggiore

HQ country

Italy

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Contract Manufacturing Services: Pharmaceutical contract development and manufacturing organization (CDMO) providing production, packaging, and R&D services to pharmaceutical clients globally. Revenue generated through project-based contracts for formulation, validation, industrialization, and commercial production.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Doppel Farmaceutici is an Italian Contract Development and Manufacturing Organization (CDMO) providing pharmaceutical formulation development, production, and packaging services for solid, semi-solid, liquid, injectable, and spray dosage forms. The company serves global pharmaceutical clients across the full drug lifecycle from discovery and R&D through validation, industrialization, and commercial production, operating dual manufacturing sites in Cortemaggiore (44,000 sqm) and Milan-Rozzano (25,000 sqm) with capacity of 100 million packages per year.

Product overview

Doppel Farmaceutici is an all-in-one Italian CDMO (Contract Development and Manufacturing Organization) offering a vertically integrated portfolio spanning pharmaceutical manufacturing, packaging, and R&D services. The core offering consists of Production/Manufacturing (solid, semi-solid, liquid, injectable, and spray forms), Packaging (clinical and commercial), R&D (formulation, validation, regulatory support, bioequivalence studies), and Start-up & Academia (spin-off and early-innovation support). Products include solid dosage forms (tablets, capsules), liquid/spray solutions (syrups, drops), semi-solid formulations (creams, gels), sterile/injectable products, and medical devices. The company operates two manufacturing sites in Milan (25,000 sqm) and Cortemaggiore (44,000 sqm), with 19 production lines and a capacity of 100 million packages per year. Alfa Omega, an associated brand, notably manufactures Class III injectable medical devices.

Differentiator

Problem solved

Functional benefit

Products and services

• Production / Manufacturing
• Packaging Clinical and commercial packaging solutions for capsules, tablets, syrups, creams, and single-dose formats, including GMP-compliant clinical trial packaging and labeling.
• R&D (Research & Development) Pharmaceutical formulation development, validation and industrialization, regulatory support, and bioequivalence/clinical study services spanning from lab phase to commercial-scale production.
• Start-up & Academia Support services for startups, academic spin-offs, and research centers including tailored formulation, prototyping, stability testing, innovative packaging, and co-development partnerships.
• Solid Dosage Forms Coated and uncoated tablets and hard and soft gelatin capsules, produced on highly automated lines with fluid bed granulation and high-speed compression, including HPAPI handling areas.
• Liquid and Spray Solutions Syrups, oral solutions, nasal sprays, drops, and mouthwashes in plastic or glass containers, with single-dose filling and innovative reservoir cap systems.
• Semi-Solid Formulations Creams, gels, lotions, and vaginal suppositories produced on lines designed for varying viscosities with CIP/SIP systems and integrated quality control.
• Sterile and Injectable Products Low-volume injectable solutions in vials, sterile products, and sterile vaginal douches produced in classified environments and barrier systems meeting European GMP and FDA standards.
• Medical Devices Class I-III medical devices including semi-solid-based devices and injectable medical devices, with Alfa Omega serving as the manufacturer of the first Class III injectable medical device.

Quantifiable outcome

• 100 million packages produced per year capacity
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered core and minor.

• MipharmcoreStrategic or Co-development Partner · 24 July 2024Mipharm, backed by Alto Partners, merged with Doppel Farmaceutici in July 2024 to form Domixtar Pharmaceuticals. The merger leverages combined expertise, scale-up capacity, and advanced technology to serve a broader range of drug development needs, creating the largest independent Italian CDMO.
• DietopackminorStrategic or Co-development Partner · 1 January 2020Doppel acquired 90% of Dietopack in 2020, one of Italy's leading CDMOs (Contract Development and Manufacturing Organizations), strengthening its presence in the pharmaceutical contract manufacturing sector.

Scale indicators6 records

Recent moves10 records

Expansion highlights5 records

Direct peers

• CordenPharma: European CDMO offering API, sterile injectable, and finished dosage form manufacturing. Comparable to Doppel in sterile and injectable capabilities with a similar B2B contract development and manufacturing model.
• Recipharm: European CDMO offering contract development and manufacturing of oral solids, semi-solids, sterile liquids, and APIs. Closely comparable business model and dosage-form mix to Doppel, primarily serving European pharma clients.
• Fareva: French pharmaceutical CDMO offering contract manufacturing of solids, semi-solids, liquids, injectables, and sterile products. Directly comparable to Doppel across dosage forms, with broader European footprint and similar B2B pharma client base.
• Aenova Group: German-headquartered CDMO providing solid, semi-solid, liquid, and sterile manufacturing plus packaging services. Direct comparable in dosage-form breadth and European B2B pharma contract manufacturing focus.
• Mipharm (now part of Domixtar Pharmaceuticals / DMX Pharma): Italian CDMO specializing in semi-solid, liquid, and sterile pharmaceutical manufacturing. Direct peer to Doppel with overlapping dosage forms; merged with Doppel in 2024 to form Domixtar Pharmaceuticals, the largest independent Italian CDMO.

Broad incumbents

• Lonza: Swiss-headquartered global CDMO with leading positions in small-molecule API, biologics, and cell/gene therapy manufacturing. Overlaps with Doppel's contract manufacturing model but with much broader modality and geographic coverage.
• Catalent: Global CDMO offering formulation, development, and manufacturing across oral, sterile, and biologic dosage forms. Comparable to Doppel in oral solids and injectable CDMO services but at vastly larger scale with multi-continent footprint.

Regional players

• Olon: Italian API and CDMO group offering active pharmaceutical ingredient development and manufacturing. Adjacent peer to Doppel with overlapping Italian base and contract pharma services, though more focused on API than finished dosage forms.
• BSP Pharmaceuticals: Italian CDMO specializing in sterile injectable and oncological pharmaceutical manufacturing. Comparable to Doppel's sterile injectable capabilities with focus on high-potency oncology products, also based in Italy.
• Chemo (Insud Pharma): Spanish-headquartered pharmaceutical group with CDMO operations in API synthesis, finished dosage forms, and biologics. Comparable European CDMO peer with similar exposure to generics and branded pharma contract manufacturing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/doppelfarma
• LinkedInlinkedin.com/company/doppel-farmaceutici-srl

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Doppel Farmeceutici